公开(公告)号：US20240277772A1

公开(公告)日：2024-08-22

申请号：US18566349

申请日：2022-05-30

申请人： SCM LIFESCIENCE CO., LTD. ,  TERAIMMUNE, LLC

发明人： Sun Uk SONG ,  Si Na KIM ,  Jeong Hyun MOON ,  Jeong Heon YOON ,  Na Ri BYUN

IPC分类号： A61K35/28 ,  A61K8/98 ,  A61K35/17 ,  A61K39/00 ,  A61P17/04 ,  A61P37/06 ,  A61Q19/00 ,  C12N5/0775

CPC分类号： A61K35/28 ,  A61K8/981 ,  A61K35/17 ,  A61K39/4611 ,  A61K39/4621 ,  A61K39/46433 ,  A61P17/04 ,  A61P37/06 ,  A61Q19/00 ,  C12N5/0663 ,  C12N2500/24 ,  C12N2500/38 ,  C12N2501/25

摘要： The present invention relates to: a composition and a kit for preventing, alleviating or treating atopic dermatitis, comprising primed function-enhanced stem cells and regulatory T cells; and a method for preventing, alleviating or treating atopic dermatitis by using same. When function-enhanced stem cells, of the present invention, treated with TNF-α, IFN-γ and IFN-α or TNF-α, IFN-γ, IFN-α and vitamins are treated in combination with regulatory T cells, the imbalance of Th1/Th2 cells of an atopic dermatitis patient can be alleviated and the status of the atopic dermatitis patient can be shifted to Th1, and thus the present invention can be widely used in various fields of prevention, alleviation or treatment of atopic dermatitis.

公开(公告)号：US12042486B2

公开(公告)日：2024-07-23

申请号：US17293941

申请日：2019-06-13

申请人： YUNNAN HAOPY PHARMACEUTICALS LTD

发明人： Xianguo Liu ,  Biao Li ,  Qiongfen Wu

IPC分类号： A01N37/00 ,  A01N25/00 ,  A01N37/12 ,  A01N37/44 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K9/28 ,  A61K9/48 ,  A61K9/70 ,  A61K31/215 ,  A61K31/24 ,  A61K31/439 ,  A61K47/02 ,  A61K47/44 ,  A61P17/04

CPC分类号： A61K31/439 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/2013 ,  A61K9/2059 ,  A61K9/28 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/4891 ,  A61K9/7053 ,  A61K47/02 ,  A61K47/44 ,  A61P17/04

摘要： The present disclosure belongs to the field of pharmaceuticals. Disclosed is a use of bulleyaconitine A in treating pruritus or a secondary lesion thereof, especially pruritus induced by histamine and/or chloroquine.

公开(公告)号：US12029743B2

公开(公告)日：2024-07-09

申请号：US16350559

申请日：2018-11-30

申请人： IVIEW THERAPEUTICS, INC.

发明人： Edward T. Wei

IPC分类号： A61K31/66 ,  A61K9/00 ,  A61K9/06 ,  A61K9/08 ,  A61K9/12 ,  A61K47/10 ,  A61P17/00 ,  A61P17/04

CPC分类号： A61K31/66 ,  A61K9/0014 ,  A61K9/0053 ,  A61K9/06 ,  A61K9/08 ,  A61K9/12 ,  A61K47/10 ,  A61P17/04

摘要： The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of dermatological disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; atopic dermatitis; contact dermatitis; cholestatic itch; psoriasis; sebhorrheic dermatitis; milaria rubra; ocular pain and discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms); and pruritus of the elderly. The applicant has found that topical delivery of DIPA compounds to the skin alleviates skin discomfort. The present discovery pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy of dermatological disorders.

公开(公告)号：US20240139213A1

公开(公告)日：2024-05-02

申请号：US17867512

申请日：2022-07-18

申请人： ALLERGYINTELLECT, INC.

发明人： Robert McDermott ,  Neal Jain

IPC分类号： A61K31/593 ,  A61K35/742 ,  A61K35/747 ,  A61P17/04 ,  A61P37/08

CPC分类号： A61K31/593 ,  A61K35/742 ,  A61K35/747 ,  A61P17/04 ,  A61P37/08

摘要： The present disclosure provides a composition comprising a first amount of a Vitamin D compound and a second amount of a probiotic compound. The disclosure also provides a method of treating an atopic condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the composition detailed herein.

公开(公告)号：US20240122952A1

公开(公告)日：2024-04-18

申请号：US18262344

申请日：2022-01-21

申请人： PROLACTA BIOSCIENCE, INC.

发明人： Biranchi PATRA ,  Adam SUN ,  Victoria NIKLAS

IPC分类号： A61K31/702 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61K35/20 ,  A61P17/04 ,  A61P17/06

CPC分类号： A61K31/702 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/107 ,  A61K35/20 ,  A61P17/04 ,  A61P17/06

摘要： Provided herein are compositions, such as topical formulations, that contain one or more fractions, portions, or components of human milk and methods of using and manufacturing the same. In some aspects, the provided compositions include human milk cream or one or more fatty acids found in or native to human milk. Also included are methods for treating or preventing skin conditions, such as atopic dermatitis or psoriasis.

公开(公告)号：US20240101690A1

公开(公告)日：2024-03-28

申请号：US18193393

申请日：2023-03-30

申请人： Kiniksa Pharmaceuticals, Ltd.

发明人： John Paolini ,  Rohan Gandhi ,  Zamaneh Mikhak

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P17/04 ,  G01N33/53

CPC分类号： C07K16/2866 ,  A61K39/3955 ,  A61P17/04 ,  G01N33/53 ,  A61P17/00

摘要： The present invention provides, among other things, methods of treating pruritic or inflammatory skin diseases or in disorders, or pruritus associated with a disease or disorder, with an anti-OSMRβ antibody, including methods of treating pruritus, in associated with atopic dermatitis, chronic kidney disease-associated pruritus, uremic pruritus or prurigo nodularis, chronic idiopathic pruritus, chronic idiopathic urticaria, chronic spontaneous urticaria, cutaneous amyloidosis, lichen simplex chronicus, plaque psoriasis, lichens planus, inflammatory ichthyosis, mastocytosis and bullous pemphigoid, comprising a step of administering to a subject in need of treatment an anti-OSMRβ antibody at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of the disease or disorder relative to a control.

公开(公告)号：US20240099976A1

公开(公告)日：2024-03-28

申请号：US18490255

申请日：2023-10-19

申请人： Sequessome Technology Holdings Limited

发明人： William HENRY ,  Richard Wolf GARRAWAY

IPC分类号： A61K9/127 ,  A61K8/04 ,  A61K8/14 ,  A61K9/00 ,  A61K9/10 ,  A61K31/155 ,  A61K31/165 ,  A61K31/355 ,  A61K31/522 ,  A61K31/60 ,  A61K31/618 ,  A61K31/7008 ,  A61K31/737 ,  A61K47/24 ,  A61K47/26 ,  A61P17/04 ,  A61P17/10 ,  A61Q19/00 ,  A61Q19/02 ,  A61Q19/08

CPC分类号： A61K9/1272 ,  A61K8/04 ,  A61K8/14 ,  A61K9/0014 ,  A61K9/10 ,  A61K9/127 ,  A61K31/155 ,  A61K31/165 ,  A61K31/355 ,  A61K31/522 ,  A61K31/60 ,  A61K31/618 ,  A61K31/7008 ,  A61K31/737 ,  A61K47/24 ,  A61K47/26 ,  A61P17/04 ,  A61P17/10 ,  A61Q19/00 ,  A61Q19/02 ,  A61Q19/08 ,  A61K33/30

摘要： The present invention relates to a formulation comprising blends of formulations (or colloidal dispersions) and its topical application. The formulation comprises at least two different types of colloidal dispersion comprising deformable colloidal particles, wherein the deformable colloidal particles comprise a non-ionic surfactant and/or a phospholipid. The deformable colloidal particles of the invention may comprise an agent of interest (AOI) or may be free of an AOI. The formulation may comprise an AOI that is not associated with the deformable colloidal particles. The present invention also includes kits comprising the formulation of the present invention and the use of the formulation in medicine, skin care and cosmetics.

公开(公告)号：US20240033252A1

公开(公告)日：2024-02-01

申请号：US18483615

申请日：2023-10-10

申请人： Clexio Biosciences Ltd.

发明人： Yael ROSEN ,  David DANGOOR ,  Richard FISHER

IPC分类号： A61K31/4174 ,  A61P17/04 ,  A61K9/00 ,  A61K45/06

CPC分类号： A61K31/4174 ,  A61P17/04 ,  A61K9/0014 ,  A61K45/06

摘要： The present disclosure related to methods of treating pruritus in a subject by topically administering detomidine, or a pharmaceutically acceptable salt thereof, to the subject.

公开(公告)号：US20240010698A1

公开(公告)日：2024-01-11

申请号：US18018642

申请日：2021-07-30

申请人： ILC THERAPEUTICS LIMITED

发明人： William STIMSON ,  Christopher MCKENZIE

IPC分类号： C07K14/56 ,  C12N15/70 ,  A61P17/04

CPC分类号： C07K14/56 ,  C12N15/70 ,  A61P17/04

摘要： The present invention relates to compositions and methods for preventing or treating canine pruritic disease, optionally wherein the canine pruritic disease is canine atopic dermatitis (AD) in general, and a synthetic canine interferon (IFN)-alpha (α) for use in said treatment or prophylaxis in particular, as well as a composition and method comprising the same and a method of production of the synthetic canine interferon-alpha.

公开(公告)号：US20230404925A1

公开(公告)日：2023-12-21

申请号：US18249869

申请日：2021-10-25

申请人： Elanco US Inc.

发明人： Stephen STIRM

IPC分类号： A61K9/28 ,  A61K31/519 ,  A61K9/14 ,  A61P17/04 ,  A61K47/02 ,  A61K47/38

CPC分类号： A61K9/28 ,  A61K31/519 ,  A61K47/38 ,  A61P17/04 ,  A61K47/02 ,  A61K9/14

摘要： The present disclosure provides compositions of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile having a specific acceptance value and/or particle size distribution, pharmaceutical compositions comprising the same, methods of using the same, and processes for making the same.